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Abstract
This paper describes the generation, characterisation and potential applications of a panel of novel anti-prion protein
monoclonal antibodies (mAbs). The mAbs were generated by immunising PRNP null mice, using a variety of regimes, with a
truncated form of recombinant ovine prion protein spanning residues 94–233. Epitopes of specific antibodies were mapped
using solid-phase Pepscan analysis and clustered to four distinct regions within the PrP molecule. We have demonstrated
the utility of these antibodies by use of Western blotting and immunohistochemistry in tissues from a range of different
species affected by transmissible spongiform encephalopathy (TSE). In comparative tests against extensively-used and
widely-published, commercially available antibodies, similar or improved results can be obtained using these new mAbs,
specifically in terms of sensitivity of detection. Since many of these antibodies recognise native PrPC, they could also be
applied to a broad range of immunoassays such as flow cytometry, DELFIA analysis or immunoprecipitation. We are using
these reagents to increase our understanding of TSE pathogenesis and for use in potential diagnostic screening assays.
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Introduction
Transmissible spongiform encephalopathies (TSEs) are a group
of fatal neurodegenerative diseases that affect both animals and
man and include bovine spongiform encephalopathy (BSE),
scrapie and variant Creutzfeldt-Jakob disease (vCJD). Individuals
affected with TSEs show long incubation periods before the onset
of clinical signs. TSE infection is accompanied by the molecular
conversion of a host-encoded glycoprotein, PrPC, into a diseased-
associated aggregated isoform (PrPSc, [1]); this isoform is partially
resistant to proteolytic degradation and accumulates in the brain
of infected individuals and often in peripheral tissues prior to
neuroinvasion. Both PrPC and PrPSc can be differentially
glycosylated (at asparagine residues 184 and 200, ovine sequence),
possess a single disulphide bond and carry a C-terminal
glycosylphosphatidylinositol anchor; whilst PrPC and PrPSc have
the same primary structure, they differ both in their biochemical
properties (such as solubility in detergents, resistance to proteolytic
cleavage, denaturation with chaotropes i.e. guanidium) and
secondary and tertiary structure. Following treatment with
proteinase K (PK), different forms of PrP, which vary in relative
molecular mass and result directly from differential cleavage events
that are related to the strain of TSE agent, can be observed in
animals and humans using both Western blotting and immuno-
histochemical approaches in an antibody-dependent manner [2–
6]. In mammals, DNA encoding the open reading frame of PRNP
is relatively well conserved and exhibits approximately 90%
similarity across species [7]. Variation does, of course, exist in the
PRNP gene within and between species. The most notable and
well characterised examples of polymorphism (which are often
associated with susceptibility to prion disease [8–10]) within an
animal species are found in sheep and goats. In sheep, a 3-letter
nomenclature is used to describe the most common alleles, where
each letter denotes the amino acid encoded at the specific codon.
A(alanine)136 R(arginine)154Q(glutamine)171 (ARQ) describes the
wild type allele in sheep, but multiple variants have been identified
such as the V (valine) RQ, ARR and ARH (where H is histidine)
alleles [11,12], as well as polymorphisms at other codons. Between
species, variation in the primary sequence of PrP may elicit
biological/functional effects, whereby, the outcome is naturally
dependent on the change itself. For example, amino acid variation
between codons 106–112 (human numbering) strongly influences
the binding of the antibody 3F4 [13,14].
A major aim of TSE research is the development of research
tools that are applicable to multiple species, have utility in a wide
range of immunoassays, have the potential to discriminate
between PrPSc and PrPC and/or may be used to develop
diagnostic tests or therapeutic regimes. To date, this has been
achieved, in part, by a number of academic research groups [15–
21] and commercial companies with notable examples including,
but not limited to, the anti-PrP antibodies P4 and L42 [22], 8H4
[23], KG9/FH11 and BG4 (The Roslin Institute, (http://www.
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roslin.ed.ac.uk/tseresourcecentre)), 6H4 and 15B3 [24], 3F4 [25],
12B2/94B4 and 100B3 (www.wageningenur.nl/prionantibody),
T1 and T2 [20], The SAF/Sha (including Sha 31) and BAR-series
of antibodies [26], the ‘R’-series of antibodies i.e. R145 [27], the
POM monoclonals [28], the ‘ICSM’ antibodies [29].
Our interest in developing our own panel of prion antibodies
was to replace commercially available antibodies, which at the
time were expensive and did not provide in some cases the
required sensitivity, for use as antigen capture and detector in
sandwich immunoassays and other routine TSE confirmatory
assays. We considered making new antibodies at a time when there
was limited availability of a range of antibodies with cross
reactivity to different species, especially sheep/ruminants and also
a limited range of epitopes recognised. To generate a panel of
‘broad spectrum’ anti-PrP antibodies, we immunised PRNP2/2
null mice with an N-terminally truncated form (spanning residues
94–233) of recombinant ovine PrP (abbreviated as recOvPrP, 94–
233). A truncated protein was used to avoid generating antibodies
that the epitope would be in the N terminal region of PrP, which is
cleaved following treatment with proteinase K (PK). We rational-
ised that the resultant antibodies would cross react with PrP of
species other than sheep by virtue of the high degree of homology
of PrP across mammalian species.
We report a unique collection of 28 new PrP antibodies and
show the utility of many of these in Western blotting and IHC
analyses of tissues from TSE-infected animals. Using Pepscan
analyses, the epitopes of the antibodies have been located to 4
discrete regions within the central and C-terminal domains of the
PrP molecule. Interestingly, not all of the antibodies were
amenable to Pepscan mapping, suggesting that some may
recognise conformational epitopes. The reagents have a broad
species-specificity and many cross react with multiple TSE agents.
In comparative analysis with commercially available prion
antibodies, similar or better results can be achieved. We offer
these new tools for collaborative projects designed to increase
knowledge of TSE agents in natural and experimental systems, for
the development of screening assays or diagnostic tests and for
therapeutic intervention strategies.
Materials and Methods
Animals/tissues Used in this Study and Ethics Statement
All animal work was reviewed and approved by ethical review
panel at The Institute for Animal Health and The Roslin Institute
and conducted under the authority of Home Office. Animal tissues
were obtained from a variety of sources (typically from ongoing
studies from co-authors/collaborators) and as such are described
in detail at specific sections throughout the manuscript.
Expression, Purification and Refolding of Recombinant
Ovine PrP (Residues 94–233, ARQ Allele)
For immunisation and in-vitro assays, a truncated form of
recombinant ovine PrP spanning residues 94–233 (ovine number-
ing, recOvPrP, 94–233, ARQ allele) was prepared according to
published methods [30–32]. Briefly, the protein was expressed
from the pTrc plasmid, hence incorporates an N-terminal hexa-
histidine tag, in 1B392 Escherichia coli cells and protein-containing
inclusions bodies were isolated by centrifugation after enzymatic
lysis. Protein was solubilised in a urea-containing buffer and was
purified, under reducing conditions, by sequential chromatogra-
phy steps based on immobilised nickel ion affinity and cation
exchange resin. After overnight oxidation of the disulphide bond
by copper ion catalysed oxidation, the urea was removed by
dialysis into 50 mM sodium acetate, pH5.5. The final protein
solution was adjusted to a final concentration of 0.5 mg/ml in
phosphate buffered saline (PBS), pH 7.2, immediately before use
in immunisations. For Western blotting assays, recPrP from other
species were produced as described [31,33] and following the same
generic protocol as given above. For the remainder of the work,
and unless specified, the numbering of amino acids for native or
recombinant PrP corresponds to that represented by the ovine
sequence.
Immunisation Strategy
Nine young adult, PRNP2/2 mice (129 Ola, all male [34]) were
assigned to 3 separate experimental groups each consisting of 3
mice. Each experimental group was subject to a specific
immunisation regime (Table S1). Group 1 mice were immunised
subcutaneously with 40 mg recOvPrP, 94–233 emulsified in an
equal volume of Titre max (Stratech). Group 2 mice were
immunised intraperitoneally (i/p) with 40 mg recOvPrP, 94–233
mixed with Quil A (1 ml added per 10 mg recOvPrP, 94–233
immunised, stock concentration= 2 mg/ml, Superfos, Denmark).
Group 3 mice were immunised i/p with 40 mg recOvPrP, 94–233
emulsified with an equal volume of Alum (Pierce). Mice were
boosted every 4, 6 or 8 weeks after the first immunisation (as
shown in Table S1, for example mouse ID 0, in experimental
group 1 was boosted every 4 weeks after the first immunisation)
and until there was a marked difference in antibody titres
compared to that seen in pre-immune sera (see section ‘Evaluation
of antibody titres in tail blood using ELISA’). Typically, mice
received between 3 and 6 boosts, after the 1st immunisation. A pre-
immune (control) serum was collected from each mouse 9 days
before starting the immunisations. 5–7 days after each immuni-
sation, blood was collected for testing of antibody response using
an ELISA.
Preparation of Anti-sera from Tail Blood Samples
Whole blood collected from mouse tails was incubated for 1 h at
37uC, to form a clot, then centrifuged (13,000 g using a bench top
centrifuge). The supernatant was diluted 1:10 using sterile PBS,
aliquotted and frozen at 220uC until required.
Evaluation of Antibody Titres in Tail Blood Using ELISA
Wells of a microtitre plate (Falcon) were coated with full-length
recOvPrP spanning residues 25–233 (abbreviated as recOvPrP,
25–233) at a final concentration of 2 mg/ml diluted in carbonate
coating buffer. Carbonate buffer was prepared by mixing 40 ml of
0.1 M Na2CO3 (pH 11) with 60 ml of 0.1 M NaHCO3 (pH 8).
Plates were sealed and then incubated overnight at 4uC. The
supernatant was decanted and wells washed twice using PBS
containing 0.05% (v/v) Tween 20 (PBS-T, Sigma). Wells were
blocked by incubation with 200 ml of 5% (w/v) Marvel (low-fat
milk powder) prepared in PBS-T (PBS-TM) for 2.5 h at 37uC and
then washed three times using PBS-T. Sera from tail blood
samples were serially diluted in PBS-TM (1:1000 to 1:32,000) and
applied to the wells in duplicate. Negative control wells were
incubated with both PBS-TM alone and pre-immune sera samples
(diluted 1:500 in PBS-TM); positive control wells were incubated
with the anti-PrP mAb FH11, which binds an epitope within the
N-terminal domain of PrP (used at a final concentration of 1 mg/
ml prepared in PBS-TM, obtained from the TSE RC). Samples
were incubated for 1–3 h at 37uC and then washed three times
using PBS-T. Secondary antibody (peroxidase conjugated, goat
anti-mouse IgG, DAKO) was diluted 1:5000 in PBS-TM and
100 ml applied to each well (with the exception of a substrate
control well). The secondary antibody reaction was incubated for
1 h at 37uC. The plates were washed four times and then 100 ml
Highly Specific Prion Protein Antibodies
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ABTS solution (HRP substrate, Roche) added per well and
incubated for approximately 20 min. The colorimetric readout
from test and control samples was measured used a spectropho-
tometer at 415 nm.
Fusions and Cloning
MAbs were prepared using conventional hybridoma technolo-
gies [35]. Briefly, 5–6 weeks after the final boost and 5 days prior
to fusion, mice were injected with 50 mg recOvPrP, 94–233 intra-
peritoneally with no adjuvant. Four days prior to fusion mice were
injected with 50 mg recOvPrP, 94–233 (no adjuvant) intravenous-
ly. Spleens were removed, cell suspensions were fused with mouse
myeloma cell line SP2/0 and hybrids were selected in hypoxan-
thine-aminopterin-thymidine (HAT) medium. Supernatants from
cell cultures were screened by dissociation-enhanced lanthanide
fluorescent immunoassay (DELFIA, see section Screening of
culture supernatants using DELFIA and [36]), positive wells were
selected (on the basis of giving highest reading compared to
positive and negative controls) and cells were cloned by limiting
dilution. Seven fusions were prepared resulting in the production
of 28 antibodies in total (Table S1). The nomenclature of the
mAbs correlates to the identification of the plate, row and well
number of the final cloned antibody i.e. mAb BC6 originated from
plate B, row C, well 6. Additionally, all antibodies are pre-fixed
with the identification ’ROS’ indicating their derivation from the
Roslin Institute i.e. ROS-BC6. The isotype of each mAb was
determined using mouse monoclonal isotyping kits (Roche Isostrip
or equivalent).
Screening of Culture Supernatants Using DELFIA
Briefly, 96-well plates (Wallac) were coated with 0.2 mg/well
purified recOvPrP, 25–233, overnight at 4uC. The supernatant
was removed and wells were washed twice with PBS before
blocking with 2% (w/v) BSA/PBS buffer, pH 7.2 for 1 h with
agitation. 100 ml of culture fluid supernatant was added to each
well for 1 h at room temperature with agitation. FH11 was applied
to control wells at a concentration of 1 mg/ml. After 3 washes (PBS
buffer) europium-labelled goat anti-mouse IgG (Dako) was diluted
1:10,000 in assay buffer (Wallac) and incubated for 1 h at room
temperature. After a final wash step, 200 ml of enhancement
solution (Wallac) was added to each well and incubated for 10 min
at room temperature with agitation. Plates were analysed using the
Victor 1420 multi-label counter (Perkin Elmer/Wallac). Each
clone’s specificity for both ovine recPrP and PK-resistant PrPSc
was also tested in other immunoassays (including flow cytometry
(not shown), Western blotting or immunohistochemistry (IHC)).
Growth, freezing, thawing and expansion of cloned supernatants
were conducted in accordance with standard procedures [35].
Purification of mAbs
Antibodies were purified from culture fluid supernatants by use
of HiTrap protein G HP columns (GE Healthcare). Columns were
equilibrated with 0.1 M Tris-HCl, pH 8.0. Culture fluid super-
natants were adjusted to pH 8.0 by the addition of 1 M Tris-HCl,
filtered using a 0.45 mm membrane and loaded onto the column.
After washing, using 0.1 M Tris-HCl, pH 8.0, column-bound
mAbs were eluted using 0.1 M glycine, pH 2.5. Immediately, the
eluted mAb was restored to pH 8.0 by the addition of 1 M Tris-
HCl and dialysed into PBS buffer, pH 7.4. Protein concentration
was estimated by measuring absorbance at 280/320 nm using a
DU-650 spectrophotometer (Beckman). The mAb concentration
was calculated on the basis of an absorbance of 1 Au280
corresponding to 0.75 mg/ml. This correlates to an estimated
extinction coefficient of ,200,000 M21.
Epitope Mapping Using Pepscan Analysis
Solid phase synthesis of peptides on a plastic surface and
immunoscreening by ELISA was carried out at the laboratory of
Pepscan Systems BV (Lelystad, The Netherlands) according to
established procedures [37,38]. In brief, complete sets of
overlapping 15-mer peptides were synthesized covering the amino
acid sequences of both ovine and bovine PrP. Each unique 15-mer
peptide was incubated with purified antibodies (tested at a range of
concentrations and optimized for each antibody tested) in an
ELISA-formatted assay. Peptide sequences were considered
antigenic when the absorbance values of two or more consecutive
peptides were at least three times greater than that of the
background. Background levels were calculated as the mean
absorbance measured for 20 consecutive, low reactive peptides
(whereby, the standard deviation was less than 20% of the mean
absorbance).
SDS-PAGE and Western Blotting
Recombinant protein. RecPrPs, typically 25–50 ng, were
diluted in LDS sample buffer (Invitrogen) under reducing
conditions and resolved using 12% NuPAGE Bis-Tris gels
(Invitrogen) prior to transfer to PVDF membrane (Millipore) for
1 h 30 min at 1.2 cm2/A. Proteins tested were: recOvPrP ARQ
allele (25–233 and 94–233), mouse (Prnpa allele, residues 23–230
murine sequence); hamster (wild type allele, residues 23–231);
bovine (residues 25–241 bovine sequence) and human (M129,
residues 23–230 human sequence).
Brain tissue and preparation of PK-resistant PrPSc. Brain
tissue from TSE-infected animals were homogenised in sterile PBS
buffer, pH 7.2 producing a 10% (w/v) homogenate. Typically,
500 ml of homogenate was treated with sodium phosphotungstic acid
(NaPTA) following digetsion with PK treatment as described in
McCutcheon et al. [36] with the following deviations: brain samples
were not given a clearing spin (80 g 1 min [39]) prior to the MgCl2
buffer and benzonase treatment and the final pellets were
resuspended in 100 ml volumes. Proteins were separated using either
10 or 12% NuPAGE Bis-Tris gels (Invitrogen) and then transferred
to PVDF membrane (Millipore) for 1 h 30 min at 1.2 cm2/A. A
range of different species/TSE disease combinations were tested and
are shown in Table S2, including ovine scrapie (naturally infected
cases), ovine CH1641 scrapie, ovine atypical scrapie, ovine BSE,
caprine scrapie and BSE, bovine BSE and deer BSE. All of these
materials were provided by co-authors involved in the study with the
exception of the scrapie-infected goat brain; bovine BSE macerate
and BSE-infected goat brain (see acknowledgements).
Immunodetection of recPrP and PK-resistant PrPSc on
PVDF membranes. Membranes were blocked using 5% (w/v)
Marvel (non-fat) milk powder/PBS buffer, pH 7.2, containing
0.1% (v/v) (PBS-T) and then incubated overnight at 4uC with the
different mAbs (typically at 1–0.1 mg/ml). After washing with PBS-
T, the membrane was incubated in peroxidase-conjugated goat
anti-mouse IgG (Sigma) for 1 h at room temperature (working
dilution of 1:20,000). After a final wash step, bound antibodies
were visualised on ECL Hyperfilm (Amersham) using West Pico
enhanced chemiluminescence substrate (Pierce). Hyperfilm was
scanned and the digital image processed using Adobe Photoshop.
Image processing was restricted to cropping, montage creation
and annotation. Sha 31 [40], P4 [22] 6H4 ([24]) and 12B2 ([41])
were purchased from Bio-Rad/SPI-Bio, R-Pharma, Prionics and
CVI, Wageningen UR respectively.
Brain tissue preparation and deglycosylation of PrPC
using peptide N–glycoside F (PNGase F). Brain material for
this work was obtained from 7 sheep in the Roslin Institute
Cheviot flock [9]. Sheep had either ARQ/AHQ, ARQ/ARQ or
Highly Specific Prion Protein Antibodies
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AHQ/AHQ PRNP genotypes. PrPC was extracted from brain
(cortex) as described in [42]. In brief, tissue was manually
homogenised in lysis buffer (containing 5% NP-40 (v/v),
12.1 mM sodium deoxycholate in PBS and protease inhibitors)
to a 10% (w/v) homogenate. The homogenate was clarified by
centrifugation and frozen until required. BCA (bicinchoninic acid)
assays (Pierce) were performed on homogenates to establish total
protein concentration. All reagents were provided with the kit and
protocol followed according to the manufacturers instructions.
PrPC in brain was deglycosylated, resolved using SDS and
immunoblotted as described in [42]. ROS-BC6 was used at a
final concentration of 0.3 mg/ml in 0.5% blocking reagent and
incubated overnight. Murine a-tubulin (NeoMarkers, Fisher) was
used at a final concentration of 0.01 mg/ml in 0.5% blocking
reagent and incubated for 1 hour.
Immunohistochemistry
Immunohistochemistry (IHC) for detection of PrP ind
tissues from multiple host species with five different ROS-
antibodies. Brain and lymphorecticular tissues from sheep,
cattle, goats and deer naturally exposed or experimentally infected
with different sources of scrapie or BSE, as described in detail in
Table S2, were examined for the presence of PrPd by IHC. The
detailed IHC protocol has been described elsewhere and sections
counterstained with Mayer’s haematoxylin [43,44] and details on
the final concentration of the five antibodies used is given in Table
S3. Positive and negative control tissues were included to verify
sensitivity and specificity of the IHC procedure.
PrP in Scrapie Infected M ouse Br-
d
Amodified version of methods described in
mm) were cut from the brains of end-stage CV (C57Bl x VM F1)
ml of 1% (w/v)
ME7 or 87V-infected brain homogenate. Antigens were retrieved
by autoclaving in a 0.1 M citric acid buffer (pH 6.4) for 15 min at
121uC before subsequently exposing to formic acid for 10 min.
Sections were washed and endogenous peroxidase was blocked
with 1% (v/v) H2O2 in methanol for 20 min. After washing, non-
specific immunolabelling was blocked by incubation with an
appropriate serum (10% v/v) for 20 min, before incubation
overnight with mAbs ROS-BH1, 6H4 (Prionics, Lot
H1001419M45) or TNP (IgG isotype control, BD Biosciences)
antibodies at final concentrations of 0.2, 3 and 0.2 mg/ml
respectively. Sections were subsequently incubated at room
temperature for 1 h using an appropriate biotinylated secondary
antibody and 30 min with ABC reagent (Vector Laboratories).
Reactivity to the secondary antibody was visualised using
diaminobenzidine (DAB, Vector Laboratories). Positive and
negative tissue controls were included to verify sensitivity and
specificity of the IHC procedure.
Results and Discussion
Antibody Generation and Isotyping
A panel of new anti-PrP antibodies was generated by
immunising nine PRNP2/2 mice with an N-terminally truncated
form of ovine recombinant protein (recOvPrP, residues 94 to 233,
ARQ allele). Different immunisation strategies and boosting
regimes were employed to attempt to generate antibodies with
different properties (Table S1). Mice were immunised with
recOvPrP, 94–233 combined with either Titre max, Quil A or
Alum as adjuvant and boosts were performed every 4, 6 or 8 weeks
after the initial priming immunisation i.e. mouse ID 0, in
experimental group 1 was boosted every 4 weeks after the first
immunisation. When antibody titres in tail blood reached maximal
levels, spleens were harvested and resultant cell suspensions fused
with a myeloma cell line. In the interests of time, spleens from
mice with the identifications 1(1), 2(0) and 3(2) were pooled and a
single fusion prepared (F782). Seven fusions were prepared in
total. Each fusion produced 1000 viable clones of which the
specificities for recOvPrP, PrPC and PK-resistant PrPSc were
tested. Four monoclonal antibodies were produced from each
fusion and isotyping showed that all antibodies generated were
IgG with variability only in the subclasses (IgG, IgG2a and IgG2b,
Table 1). Of the 28 monoclonal antibodies generated, only 18
(listed in Table 1) were selected for further characterisation using a
range of immunoassays, including immunohistochemistry, West-
ern blotting and epitope mapping using Pepscan analysis.
Antibody Binding Regions are within the Central Region
and C-terminus of PrP
To map the epitopes of the antibodies, Pepscan analysis was
undertaken by use of overlapping, 15-mer peptides based on the
ovine sequence of PrP. Figure 1 shows representative outputs of
Pepscan analysis for the antibodies ROS-DC12, ROS-FH10,
ROS-BC6 and ROS-IH9; increases in the relative absorbance
above a pre-defined threshold indicate antibody binding a
particular series of overlapping peptides. For example, ROS-
BC6 bound to peptides 141 to 144, allowing the epitope to be
localised within the sequence 144FGNDYEDRYYR154. The core
epitopes of antibodies which were reactive in Pepscan are
summarised in Table 1, alongside the commercially available
antibodies Sha 31, P4, 6H4 and 12B2.
By comparing the epitope of all the antibodies mapped, it
became clear that they segregate into four distinct binding regions,
designated as groups 1–4. All group 1 mAbs bind to the amino
acid sequence 140PLIHFG145, which precedes helix 1 of the PrP
molecule. Group 2 antibodies recognise an area spanning amino
acids 143–157, within helix 1, and in which the DRYY motif
formed the consensus binding area for those antibodies. The
epitope of ROS-FH10 was identified at the start of helix 3,
proximal to the second glycosylation site, and was composed of
amino acids 202–210, TETDIKIME. The epitope of the group 4
antibodies was mapped to a sequence in the extreme C-terminal
region of PrP, spanning residues 222–231, RESQAYYQR, and in
which the common consensus sequence was 225SQAYYQ230. The
positioning of these four distinct core binding regions on the
tertiary structure of the globular domain for ovine PrP is illustrated
in Figure S2. Not all of the antibodies tested using Pepscan
mapped to linear binding sequences (i.e. ROS-FD12, ROS-EA6
and ROS-JC4), implying that these antibodies may recognise
conformational epitopes composed of amino acids that are far
apart in the linear sequence but spatially proximal in folded PrP.
Additionally, not all antibodies were tested in Pepscan analysis
(ROS-IH11 and ROS-EC9).
Multi-species Reactivity against Bacterially-expressed,
Mammalian PrP
Recombinant PrP corresponding to sheep (25–933 and 94–233
variants, 25 kDa and 17 kDa respectively) murine, hamster,
bovine and human PrP sequences were resolved using SDS-
PAGE and immunoblotted with the antibodies. Many antibodies
cross-react with all recPrPs tested, probably as a result of the high
degree of homology of the amino acid sequence of each protein in
the regions of the antibody epitopes (Figure 2). A representative
Highly Specific Prion Protein Antibodies
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and conventional VM/Dk mice inoculated with 20
[43] was used for IHC of murine tissues. Paraffin-embedded sections
ain           using ROS-BH1.  
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example of the Western blot assay is shown in Figure 3 using
ROS-DE3 and ROS-FH6 and a summary of the species cross
reactivity derived from these studies is detailed in Table 1.
However, some antibodies showed clear differential binding to the
recombinant protein panel in the Western blot assay. For example,
ROS-JB10, ROS-DC12, ROS-FH6 and ROS-EA6 bound to
ovine and bovine recPrP but not to murine or hamster. Whilst the
epitope for ROS-EA6 was not identified by use of Pepscan
analysis, the binding regions for ROS-JB10, ROS-FH6 and ROS-
DC12 were mapped to a common motif 225SQAYYQ230. It is
notable that in the hamster and murine sequences, aspartic acid
replaces glutamine at residue 230, implying that residue 230 is
critical for antibody binding in this region. For these antibodies, it
was also interesting to note the differential reactivity to human PrP
by ROS-FH6 compared to both ROS-JB10 and ROS-DC12. The
reason for this is not clear, but is conceivable that the mapping
studies, in general, may not be wholly definitive and that the
‘complete’ epitope for ROS-JB10, ROS-DC12 and ROS-FH6
may include a wider region than that defined by the Pepscan
analysis. In this context, the data could be reconciled in terms of
different amino acids expressed at residues 222 (Q/E) and/or 223
(R/K) in ovine and human sequences. ROS-HC2, which mapped
to the ovine sequence 150DRYYRENM157, bound to ovine and
murine recombinant proteins only. The failure to react with the
bovine, murine and hamster proteins appears to be associated with
amino acid differences at residues 151 (Y/W) and potentially at
149 (N/S). ROS-FD12 also showed a similar pattern of species
specificity to ROS-HC2, though the epitope for ROS-FD12 was
not determined using Pepscan.
Arginine at Codon 154 is Critical for Antibody Binding of
ROS-BC6
The epitope for ROS-BC6 was mapped to amino acids
144FGNDYEDRYYR154 (Table 1) and this antibody is used
extensively in our laboratory for routine analysis of PrPC and
PrPSc in tissues collected from sheep infected with scrapie and/or
BSE as well as healthy controls. It is known that ovine PrPC can
undergo proteolytic cleavage [45], resulting in the generation of a
C-terminal fragment designated as C1. We have used ROS-BC6
to show that the levels of C1-PrP (as a percentage of total PrP)
varied in accordance with PRNP genotype, whereby the highest
levels of C1 were seen in ARR/ARR sheep compared to both
VRQ and ARQ homozygotes. [42]. To further that analysis, we
recently investigated the relative amounts of C1-PrPC in sheep of
ARQ/AHQ, ARQ/ARQ and AHQ/AHQ genotypes. Figure 4
shows a representative Western blot probed with ROS-BC6
(0.3 mg/ml) and tubulin (T, 0.01 mg/ml) antibodies simultaneously
according to the published methods [42]. A marked reduction in
binding of ROS-BC6 to full-length PrP (,28 kDa) in brain from
AHQ/AHQ sheep compared to both ARQ/ARQ and ARQ/
AHQ was seen (comparison of lanes 3–7 with lanes 2 and 1
respectively). No C1-PrP (,17 kda) was detected in brain from
any of the AHQ/AHQ sheep tested, even upon longer exposure
times. Furthermore, coupling the data from this experiment and
Figure 1. Four distinct binding regions are identified using
Pepscan analysis. Antibodies were tested using solid-phase, PrP-
based peptide Pepscan analysis. Y-axis represents absorbance; x-axis
corresponds to the peptide set. Each peptide set is composed of 15
amino acids, whereby set number 1 starts with the residue 1 in PrP;
peptide set 2 starts at residue 2 in PrP and so on. Positive reactions
between antibodies and surface-bound peptides resulted in an increase
in absorbance (405 nm) which could be discriminated from back-
ground/‘noise’ readouts. Here we show increased absorbance indicative
of the core binding regions from individual representatives of the four
distinct antibody groups identified.
doi:10.1371/journal.pone.0091143.g001
Figure 2. Partial alignment of PrP sequences studied in this
work. Reference sequences were obtained from UniProt and aligned
using ClustalX using the sheep sequence as the reference. Segments of
the sequence corresponding to the core epitopes for the 4 groups of
antibodies are shown in bold with additional flanking sequence for
reference. Where amino acids are the same as sheep this is indicated
with a dash; where amino acids differ these are explicitly stated, or a
gap is left where no amino acids align.
doi:10.1371/journal.pone.0091143.g002
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published findings with epitope mapping result for ROS-BC6
identified that arginine at codon 154 as a critical residue for
reactivity in ovine PrP.
PK-resistant PrPSc from Multiple TSE Agents is Detected
Using the ROS Antibodies: Comparative Analysis with
Commercially Available Antibodies
One of the main aims of the research we undertake relates to
the detection of PK-resistant PrPSc extracted from tissues from
animals infected by both experimental and natural routes.
Therefore, finding optimal reagents that give superior data in
aiding that objective is critical. To this end, we selected a sub panel
of antibodies to test their ability to detect PK-resistant PrPSc/PrPd
(defined as disease-associated PrP in immunohistochemistry assays
given that tissue sections are not treated with PK) from animals
affected with different TSE agents (Table S2) in Western blotting
and immunohistochemistry assays respectively.
Figure 5 shows a series of representative immunoblots obtained
when PK-treated samples from TSE-infected animals were probed
with antibodies ROS-IH9, ROS-BC6, ROS-FH10 and ROS-
FH6, compared to the commercially available antibodies 6H4,
Sha 31, 12B2 and P4. Where possible, we standardised the
concentrations of antibodies used to a final concentration of
0.5 mg/ml. The 3 antibody-reactive protein bands correlating to
the di-, mono- and un-glycosylated forms of PrP resolved between
20–30 kDa. A lower molecular weight band, characteristic of
atypical scrapie, resolved ,10 kDa. The 10 kDa band has been
shown, for Nor 98 strain of atypical scrapie and using a
monoclonal antibody-based epitope mapping, to contain amino
acids spanning residues 93–153 of ovine PrP [6] and was detected
by commercially-available mAbs P4 and 12B2. It could have been
expected that antibodies containing epitopes assigned to group 1
and 2 (residues 140–145 and147–154 respectively) would be able
to detect the 10 kDa band characteristic of atypical scrapie in
sheep. However, only ROS-IH9 was capable of binding to this
band (frontal cortex, lane 8 in the IH9 panel). This result was
confirmed by testing frontal cortex, cerebellum and medulla
samples from greater numbers of sheep with atypical scrapie with
ROS-IH9 and ROS-BC6 (Tan et al., in preparation). Of note, the
genotype of the sheep with atypical scrapie was homozygous for
phenylalanine at codon 141, whilst the ovine sequence used for
epitope mapping contained leucine at the equivalent position,
indicating that ROS-IH9 binds the 10 kDa band when either
amino acid is present.
All of the ROS antibodies cross reacted with the majority of
strains/species combinations tested. The notable exception
observed was reactivity to PrPSc from goat scrapie (lane 2, all
panels). The reason for this is not clear, though we suggest that this
particular goat sample has lower levels of PK-resistant PrPSc than
other goat samples examined (not shown) and to the other samples
tested in this assay. Equally, these data show that the antibodies do
not have an equal affinity for all TSE agents; only antibodies with
the highest affinity will bind i.e. ROS-BC6, ROS-IH9, 12B2, Sha
31 and P4. We show that the reactivity profile of the ROS
antibodies (used singly or in combination) tested in this assay is
comparable to the profiles obtained using either of the commer-
cially-available antibodies. Of more significance than the broad
reactivity of these antibodies to different TSE agents and in a
range of infected host animals, is the comparable and in some
cases improved sensitivity of binding compared to the commer-
cially available mAbs. For example, ROS-IH9 appeared to react
with the same specificity to the TSE agents as 6H4/12B2/P4 but
with improved sensitivity i.e. better reaction to BSE samples (lanes
4 to 7) compared to 12B2 and P4 (assessed by a combination of the
concentration of antibody used and the time of exposure required
to give the same reaction profile). That said ROS-IH9 showed a
similar reactivity profile compared to Sha 31 for the agents tested.
The exceptions noted were the positive reaction of ROS-IH9 for
atypical scrapie and the positive reaction of Sha 31 for goat scrapie
sample.
Figure 3. Binding of ROS-FH6 (compared to ROS-DE3) to
mammalian PrP is affected by the sequence. Immunoblots of
recOvPrP residues 25–233 ovine sequence (lane 1), recOvPrP residues
94–233 ovine sequence (lane 2), murine (Mur) PrP residues 23–230
murine sequence (lane 3), hamster (Ham) residues 23–231 hamster
sequence (lane 4), bovine (Bov) PrP residues 25–241 bovine sequence
(lane 5) and human (Hum) PrP residues 23–230 human sequence(lane 6)
when probed with ROS-DE3 and ROS-FH6. ROS-DE3 cross reacts with all
species of mammalian PrP tested, whereas ROS-FH6 failed to bind to
murine and hamster PrP. Molecular weight markers are shown in kDa.
Exposure time is shown in minutes (m).
doi:10.1371/journal.pone.0091143.g003
Figure 4. ROS-BC6 requires arginine (R) at codon 154 for
binding to C1 PrPC. Representative image of mature-length (FL) and
C1 PrPC (C1, deglycosylated forms) extracted from brain of seven sheep
of either ARQ/AHQ (lane 1), ARQ/ARQ (lane 2) or AHQ/AHQ (lanes 3–7)
PRNP genotypes. Membrane was probed with ROS-BC6 (0.3 mg/ml)
simultaneously with anti-tubulin (T, 0.01 mg/ml). ROS-BC6 binds
specifically to mature-length and C1 PrP in brain from ARQ/AHQ and
ARQ/ARQ sheep but not from AHQ/AHQ sheep. Molecular weight
markers are shown in kDa, exposure time was 10 minutes.
doi:10.1371/journal.pone.0091143.g004
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PrPd Detection by IHC in a Range of Ruminant Hosts
Infected with Classical or Atypical Scrapie or BSE
Antibodies ROS-IH9, ROS-BH1, ROS-BC6, ROS-FH6 and
ROS-FH10 were also tested in IHC examinations of paraffin
sections from both central nervous system (CNS) and lymphor-
ecticular (LRS) tissues from the animals listed in Table S2. We
found that ROS-IH9 and ROS-BH1, used either singly or in
combination, provided superior results compared to commercially
available antibodies, in terms of sensitivity and ability to detect a
range of different PrPd types. Assays on central nervous system
(CNS) tissues were independently scored from 0 (no labelling) to 3
(most intense labelling), and results are given in Table S3 for large
animal infection models and Table S4 for small animal infection
models. Overall, ROS-IH9 gave the highest combined score
compared to the other antibodies tested. In the case of animals
tested in these assays, ROS-IH9 was capable of detecting PrPd in
the CNS of all agent/host combinations, whereas the other
antibodies failed to detect PrPd in cases of atypical scrapie,
CH1641 scrapie or both.
Figure 6 illustrates a range of PrPd types in the CNS of several
TSE examples in different species after labelling with ROS-IH9. A
range of staining patterns [44] were observed within the dorsal
motor nuclei of the vagus nerve in TSE-affected sheep. For
example, for natural sheep classical scrapie, punctuate intraneu-
Figure 5. Testing the mAb specificity for different TSE agents. PrPSc was extracted from the brain of a range of host animals infected with
different TSE agents, treated with PK and detected using SDS-PAGE and immunoblotting with the new mAbs and selected commercially available
antibodies. Natural sheep (Shp) scrapie (lane 1), goat scrapie (lane 2), CH1641 scrapie (lane 3), sheep (Shp) BSE (lane 4), goat BSE (lane 5), cow (Bov)
BSE (lane 6), deer BSE (lane 7) and atypical scrapie - frontal cortex (FC), cerebellum (C) and medulla (M) (lanes 8, 9 and 10 respectively). Molecular
weight masses are shown in kDa. Each immunoblot shows antibody concentration (mg/ml) and exposure time to film (minutes, m).
doi:10.1371/journal.pone.0091143.g005
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ronal, perineuronal and widespread fine particulate neuropil
labelling was observed in the dorsal motor nucleus of the vagus
nerve (DMNV, Figure 6A). A similar PrPd profile was seen in
sheep and goats experimentally infected with BSE albeit with
different intensities of labelling staining within neurones (Figure 6C
and 6E respectively). For agents targeting the cerebellum, diffuse
labelling of the granular cell layer as well as intracellular labelling
of glial cells in the granular and molecular cells layers was seen in
sheep infected with the CH1641 strain of scrapie (Figure 6B). For
sheep with atypical scrapie, ROS-IH9 identified widespread
accumulation of PrPd throughout the granular, molecular and
white matter of the cerebellum. In red deer infected with BSE,
intracellular labelling of Purkinje cells and Golgi neurons together
with intense extracellular deposits of PrPd throughout the granular
and molecular cell layers was observed. Figure 6G shows strongly-
labelled, conspicuous PrPd masses, coalescing and plaque-like, at
the level of the hypothalamus of a goat with nature scrapie and
Figure 6H shows coalescing PrPd aggregates in the spinal tract of
the trigeminal nerve of a case of cattle BSE. Comparative negative
control tissue sections from sheep, goat, deer and cow stained with
ROS-IH9 (at a final concentration of 0.063 mg/ml) are shown in
Figure S3, panels A to D respectively.
ROS-BH1 gives a more Sensitive Detection of Mouse
Scrapie Agents Compared to 6H4
Figure 7 shows representative PrPd deposition in the hippo-
campus and cortex during 87V infection in mice, when sections
were stained with either ROS-BH1 or 6H4. Slides were coded and
independently assessed. Using ROS-BH1 fine, punctate PrP
staining in association with plaques were evident in the cortex at
the level of the caudate nucleus, the cortex at the level of the
hippocampus and within the hippocampus. Fine punctate staining
was evident in the thalamus and hypothalamus (panels A, D and
G). Though not shown here, PrP staining was also observed within
the colliculous (fine punctate and pericellular staining), brainstem
(fine punctate) and the cerebellum (plaques within the granular cell
layer). In relative terms, the intensity of staining observed between
ROS-BH1 and 6H4 was similar, with higher scores recorded for
ROS-BH1 within the caudate nuclei, hypothalamus and collicu-
lous compared to 6H4 (Table S4). Importantly, the same profile
and pattern of PrP staining was observed when we used ROS-BH1
as that obtained when serial sections were stained with 6H4
(comparison of panels A, D and G to B, E and H respectively),
which we have routinely used for such analysis. However we used
ROS-BH1 at a 15 fold lower concentration than 6H4, indicative
of the level of sensitivity that can be achieved with this antibody.
No staining was observed when serial sections were stained with
TNP, the isotype control for both 6H4 and ROS-BH1 (panels, C,
F and I). To confirm the results with ROS-BH1 were not co-
incidental or restricted to a single TSE agent, we repeated this
assay using tissue from mice infected with ME7 scrapie (Figure S1
and Table S4). The same outcome in terms of improved sensitivity
of detection of PrPd by ROS-BH1, compared to 6H4, were
obtained.
Conclusions
This paper details the production, extensive characterisation
and applications of a panel of anti-prion protein antibodies
(designated as the ‘ROS’-series of antibodies). Notably, when
tested alongside the current world-leading antibodies, several of
these new antibodies (used singly or in combination) provide
comparable or improved results in immunoassays commonly used
for diagnosing TSE infection in multiple host species and for
investigating the biological processes underlying these diseases.
This is highly significant in terms of the cost of running high-
throughput screening assays or routine assays spanning long
experiment times typically associated with TSE infection in animal
models.
These antibodies have been used extensively in our laboratories
and distributed to other research labs for collaborative use,
resulting in several primary publications relating to: the identifi-
cation of a new form of prion protein in BSE-affected cattle (using
ROS-JB10 [46]), the production of a PrP fragment 114–188 from
PrPSc in heterozygous sheep (using ROS-FH6 [47]), assessment of
relative C1 PrPC levels in sheep of different PrP genotypes (using
ROS-BC6, ROS-FH10 and ROS-JB10 [42]), the identification of
infection and distribution of PrPSc in tissues of sheep experimen-
tally infected with BSE blood components (using ROS-BC6 [48]),
the effect of PRNP genotype on the incubation times in sheep with
Figure 6. Different profiles of PrPd staining are evident when
brain sections from TSE-infected sheep, goat, cow and deer
were stained with ROS-IH9. Labelling for PrPd in the brain (indicated
by brown staining) from several ruminant species infected with
different TSE agents using the antibody ROS-IH9 (0.0625 mg/ml).
Experimental classical scrapie in sheep specifically the dorsal motor
nucleus of the vagus nerve (DMNV, panel A); CH1641 scrapie in sheep
(cerebellum, panel B); cattle BSE in sheep (DMNV, panel C); atypical
scrapie in sheep (cerebellum, panel D); goat BSE in goat (DMNV, panel
E); cattle BSE in red deer (cerebellum, panel F); classical scrapie in goat
(hypothalamus, panel G); natural BSE in cattle (spinal tract of the
trigeminal nerve, panel H). Scale bar = 200 mm.
doi:10.1371/journal.pone.0091143.g006
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BSE (using ROS-BC6 [49]) and the characterisation of PrP
deposition and pathology associated with BSE infection in aged
and young mice (using ROS-BH1) [50].
Collectively, epitopes covered by the ROS-antibodies bind to
discrete regions within PrP, spanning residues 140–154, 202–210
and 222–230. This is of both functional and biological
significance, since data emanating from the use of antibodies with
different epitopes within PrP have yielded significant advance-
ments in prion biology relating to: diagnostic regimes for animal
TSE disease (using 6H4 [22,24,51,52] or human TSEs (using KG9
singly or in combination with other antibodies i.e. 3F4, ICMS35,
BG4 [53–56]); immunological characterisation of pathology
associated with established and emerging TSEs, such as immuno-
phenotyping of atypical scrapie using an array of antibodies [2] or
identification of the shared characteristic of Nor98 scrapie and
human Gerstmann-Straussler-Scheinker disease (GSS) [6]; the use
of sequences in the prion protein which are species specific (using
3F4 or antisera raised against synthetic peptides [14,25,57]); the
discrimination of TSE strains in large and small animal models, for
example natural scrapie, BSE and CH1641 scrapie (using P4 and
66.94ba [58], 6H4/P4 [59], P4 [60]), using triplex immunostain-
ing with L42, 12B2 and SAF84 [61] and using multiple antibody
panels [5,41,62–67]; the characterisation and classification of
human prion disease [68–71]; the characterisation of structural
elements within PrP, such as deciphering accessibility and
exposure of epitopes following the conversion of PrPC to PrPSc
or those that are PrPSc-specific i.e. the Tyr-Tyr-Arg motif [72],
15B3 [24], 6H10 [73–77] and identifying potential structural
intermediates in the PrPC to PrPSc transition [78–82].
Given the coverage of epitopes collectively represented by the
ROS-antibodies, it is conceivable that novel C-terminal truncated
forms of PrP may be identified by mapping studies using ROS-
FH10, ROS-JB10, ROS-DC12 or ROS-FH6. Furthermore, since
the primary reagents used in many current screening assays and
diagnostic tests for prion diseases are still largely antibodies, a new
reservoir of high-affinity reagents will help to improve the
sensitivities of such approaches for both humans and animals.
Knowledge of the epitopes represented by the ROS antibodies
allows for multiple combinations of antibody pairs to be evaluated
as capture and detector in sandwich-type immunoassays, with or
without pre-treatments using the enzyme PK or used to identify
the differences in exposure of cell-associated PrP epitopes in blood
from healthy or TSE infected individuals [83–88] or for immune-
capture of PrPSc/misfolded forms of PrP present in blood [89].
Figure 7. ROS-BH1 stains PrPd deposited after 87V infection in mice in a more sensitive manner compared to 6H4. Staining of PrPSc
during 87V (scrapie) infection in the cortical hippocampus, the cortex and the CA2 region of the hippocampus in mice using ROS-BH1 (0.2 mg/ml,
panels A, D and G), 6H4 (3.0 mg/ml, panels B, E and F) and the IgG1 isotype control antibody, TNP (0.2 mg/ml, panels C, F and I). Panels, G H and I are
higher magnification images of the CA2 region. Neuroanatomical landmarks are identified as follows: Fi – fimbria; Th - thalamus; DG - dentate gyrus;
CA2 - CA2 region of the hippocampus; CA1 - CA1 region of the hippocampus; Cx - cortex; V - ventricle and S - septum. Scale bars are indicated in mm.
ROS-BH1 gave more sensitive detection of PrPd in this assay compared to 6H4 whilst retaining an identical specificity and profile of staining to that of
6H4.
doi:10.1371/journal.pone.0091143.g007
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Towards a therapeutic approach, some drug therapies, such as
pentosan polysulphate and quinacrine, have shown promising
outcomes in animal studies [90,91], however they have been of
limited success in a clinical setting, in part because of toxicity
effects, inability to cross the blood-brain barrier or because
benefits are only evident if treatment is initiated around the time of
infection. A different strategy could be the use of monoclonal
antibodies for the prevention or treatment of prion diseases,
reviewed in [12,92,93] and described by Madampage et al. [94].
Favour has moved towards passive immunisation as an approach,
to reduce/prevent prion protein replication and disease progres-
sion, as opposed to active immunisation due to the potential
unwanted autoimmune effects. To be of significant benefit this
strategy may require antibodies that specifically recognise abnor-
mal forms of PrP, thereby reducing cross reactivity with abundant
levels of cellular forms of the prion protein. In addition, it is
important that anti-PrP antibodies used therapeutically do not
induce apoptosis of neurones [95,96] and the ROS series of
antibodies are currently being trialled for their potential as
therapeutic agents.
To achieve universal goals within the TSE field, such as
diagnosis of established and emerging TSE agents and achieving
new regimes for disease treatment and prevention, we continue to
invite sharing of our new monoclonal antibodies through
collaborative projects and/or independent use following purchase
from the TSE resource centre (http://www.roslin.ed.ac.uk/
tseresourcecentre) at The Roslin Institute.
Supporting Information
Figure S1 ROS-BH1 stains PrPd deposited after ME7 infection
in mice in a more sensitive manner than 6H4. Staining of ME7
(scrapie) infection in the cortical hippocampus and the CA2 region
of the hippocampus in mice using ROS-BH1 (0.2 mg/ml, panels A
and D), 6H4 (3.0 mg/ml, panels B and E) and the IgG1 isotype
control antibody, TNP (0.2 mg/ml, panels C and F). Neuroana-
tomical landmarks are identified as follows: Fi – fimbria; Th -
thalamus; DG - dentate gyrus; CA2 - CA2 region of the
hippocampus; CA1 - CA1 region of the hippocampus. Scale bars
are indicated in mm. ROS-BH1 gave more sensitive detection of
PrPd in this assay compared to 6H4 whilst retaining an identical
specificity and profile of staining to that of 6H4.
(DOCX)
Figure S2 Schematic ribbon diagram of the tertiary structure of
the globular domain of PrP. The structure is based on that solved
by crystallography by Haire et al [1] for ovine recombinant PrP
and spans residues 128 to 233. Coordinates were obtained from
the Protein Data Bank (code 1UW3) and were rendered using
MolMol [2] and Povray. The common core binding regions for
each group of antibodies are displayed as spheres representing the
a-carbon atoms of the residues involved in the binding epitope.
(DOCX)
Figure S3 Comparative negative control tissue sections from
sheep, goat, deer and cow stained with ROS-IH9. Panel A shows
the dorsal motor nuclei of the vagus nerve (DMNV) at the level of
the obex from sheep. Panel B shows the DMNV at the level of the
obex from goat. Panel C shows cerebellum from deer. Panel D
shows spinal tract from cow. Tissues were obtained from animals
known not to be infected with a TSE. All tissues sections were
stained with ROS-IH9 at a final concentration of 0.063 mg/ml.
No PrPd labelling (as indicated by the absence of brown staining)
was observed in the tissue sections tested. Scale bars = 200 mm.
(DOCX)
Table S1 Immunisation strategy.
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Table S2 Details of ruminant species used to assess five ROS-
antibodies by Western blotting (WB) and immunohistochemistry
(IHC).
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Table S3 Comparative analysis of subjective scoring for PrPd
using five different ROS- antibodies in TSE-affected ruminants.
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Table S4 Arbitrary scoring of PrPd in ME7 and 87V scrapie,
using ROS-BH1 and 6H4.
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